A. Lazar

2.1k total citations · 1 hit paper
33 papers, 1.6k citations indexed

About

A. Lazar is a scholar working on Genetics, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, A. Lazar has authored 33 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 16 papers in Epidemiology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in A. Lazar's work include Inflammatory Bowel Disease (21 papers), Microscopic Colitis (15 papers) and Pharmaceutical studies and practices (5 papers). A. Lazar is often cited by papers focused on Inflammatory Bowel Disease (21 papers), Microscopic Colitis (15 papers) and Pharmaceutical studies and practices (5 papers). A. Lazar collaborates with scholars based in Germany, United States and Netherlands. A. Lazar's co-authors include Roopal Thakkar, William J. Sandborn, Edgar Schömig, B Huang, Stefanie Schreiber, Daniël W. Hommes, G. D’Haens, Walter Reinisch, Remo Panaccione and Richard N. Fedorak and has published in prestigious journals such as Gut, Clinical Pharmacology & Therapeutics and Alimentary Pharmacology & Therapeutics.

In The Last Decade

A. Lazar

27 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

2011 683 citations Walter Reinisch, William J. Sandborn et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Lazar Germany	11	849	742	371	285	178	33	1.6k
Dario Sorrentino Italy	23	460 0.5×	517 0.7×	499 1.3×	51 0.2×	146 0.8×	62	1.7k
Kristian Bjøro Norway	27	144 0.2×	1.9k 2.6×	592 1.6×	269 0.9×	181 1.0×	79	3.0k
Nicola De Maria Italy	32	164 0.2×	1.8k 2.4×	521 1.4×	75 0.3×	104 0.6×	102	3.2k
Takayuki Iida Japan	19	1.0k 1.2×	618 0.8×	334 0.9×	34 0.1×	405 2.3×	42	1.8k
Monika Rau Germany	21	170 0.2×	1.1k 1.5×	227 0.6×	117 0.4×	206 1.2×	44	1.7k
Linda A. Feagins United States	27	771 0.9×	555 0.7×	882 2.4×	118 0.4×	252 1.4×	88	2.2k
Harald Hofer Austria	32	162 0.2×	2.7k 3.6×	537 1.4×	65 0.2×	156 0.9×	73	4.0k
Gaetano Bertino Italy	25	174 0.2×	750 1.0×	501 1.4×	54 0.2×	94 0.5×	81	2.0k
Juan Ignacio Arenas Spain	18	246 0.3×	637 0.9×	223 0.6×	33 0.1×	87 0.5×	44	1.2k
Gopal Krishna Dhali India	18	134 0.2×	1.0k 1.4×	480 1.3×	48 0.2×	113 0.6×	82	2.0k

Countries citing papers authored by A. Lazar

Since Specialization

Citations

This map shows the geographic impact of A. Lazar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Lazar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Lazar more than expected).

Fields of papers citing papers by A. Lazar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Lazar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Lazar. The network helps show where A. Lazar may publish in the future.

Co-authorship network of co-authors of A. Lazar

This figure shows the co-authorship network connecting the top 25 collaborators of A. Lazar. A scholar is included among the top collaborators of A. Lazar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Lazar. A. Lazar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dezsi, Ştefan, et al.. (2024). Trends and Future Directions in Analysing Attractiveness of Geoparks Using an Automated Merging Method of Multiple Databases—R-Based Bibliometric Analysis. Land. 13(10). 1627–1627. 2 indexed citations

Jharap, Bindia, William J. Sandborn, Walter Reinisch, et al.. (2015). Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Alimentary Pharmacology & Therapeutics. 42(9). 1082–1092. 59 indexed citations

Wolf, Douglas C., Geert D’Haens, William J. Sandborn, et al.. (2014). Escalation to weekly dosing recaptures response in adalimumab‐treated patients with moderately to severely active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 40(5). 486–497. 41 indexed citations

Griffiths, Anne M., Wallace Crandall, Richard B. Colletti, et al.. (2014). OP021 Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn's disease in the IMAgINE 1 trial. Journal of Crohn s and Colitis. 8. S12–S12. 2 indexed citations

Veereman‐Wauters, G., Wallace Crandall, A. Lazar, et al.. (2013). P311 Adalimumab treatment is associated with improved quality of life in pediatric Crohn's disease. Journal of Crohn s and Colitis. 7. S133–S134. 1 indexed citations

Ghosh, Subrata, Douglas C. Wolf, W. Sandborn, et al.. (2013). P568 Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2. Journal of Crohn s and Colitis. 7. S238–S238. 1 indexed citations

Sandborn, William J., Gert Van Assche, Roopal Thakkar, et al.. (2012). PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis: Abstract PWE-253 Table 1. Gut. 61(Suppl 2). A400.3–A401. 2 indexed citations

Colombel, J F, W. Sandborn, Gert Van Assche, et al.. (2012). P213 Benefit risk assessment of adalimumab as maintenance treatment for ulcerative colitis: Near analysis of week 8 responders in ULTRA 2. Journal of Crohn s and Colitis. 6. S94–S95. 1 indexed citations

Reinisch, Walter, et al.. (2011). 52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants: Table 1. Gut. 60(Suppl 1). A139–A140. 9 indexed citations

10.

Reinisch, Walter, William J. Sandborn, Daniël W. Hommes, et al.. (2011). Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 60(6). 780–787. 683 indexed citations breakdown →

11.

Sandborn, William J., Walter Reinisch, Roopal Thakkar, et al.. (2011). Adalimumab induction therapy improves health-related quality of life in patients with moderately to severely active ulcerative colitis.. Inflammatory Bowel Diseases. 17(suppl_1). S60–S61. 2 indexed citations

12.

Lazar, A. & Alexander Jetter. (2008). Pharmakogenetik in der Onkologie: 5-Fluorouracil und die Dihydropyrimidin-Dehydrogenase. DMW - Deutsche Medizinische Wochenschrift. 133(28/29). 1501–1504. 7 indexed citations

13.

Wyen, Christoph, Uwe Fuhr, Dorothee Frank, et al.. (2008). Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients. Clinical Pharmacology & Therapeutics. 84(1). 75–82. 67 indexed citations

14.

Tomalik‐Scharte, Dorota, A. Lazar, Uwe Fuhr, & Julia Kirchheiner. (2007). The clinical role of genetic polymorphisms in drug-metabolizing enzymes. The Pharmacogenomics Journal. 8(1). 4–15. 93 indexed citations

15.

Schömig, Edgar, A. Lazar, & Dirk Gründemann. (2006). Extraneuronal Monoamine Transporter and Organic Cation Transporters 1 and 2: A Review of Transport Efficiency. Handbook of experimental pharmacology. 151–180. 74 indexed citations

16.

Taubert, Dirk, Gundula Grimberg, A. Lazar, et al.. (2006). Impact of P-glycoprotein on clopidogrel absorption. Clinical Pharmacology & Therapeutics. 80(5). 486–501. 330 indexed citations

17.

Tomalik‐Scharte, Dorota, A. Lazar, Jean‐François Le Meins, et al.. (2005). Dermal absorption of permethrin following topical administration. European Journal of Clinical Pharmacology. 61(5-6). 399–404. 71 indexed citations

18.

Lazar, A., et al.. (2004). Multiple Organ Failure due to 5-Fluorouracil Chemotherapy in a Patient with a Rare Dihydropyrimidine Dehydrogenase Gene Variant. Oncology Research and Treatment. 27(6). 559–562. 26 indexed citations

19.

Paquet, K. J. & A. Lazar. (1994). Current Therapeutic Strategy in Bleeding Esophageal Varices in Babies and Children and Long-Term Results of Endoscopic Paravariceal Sclerotherapy over Twenty Years. European Journal of Pediatric Surgery. 4(3). 165–172. 15 indexed citations

20.

Lazar, A., et al.. (1992). Enfermedad hemolítica neonatal ABO: diagnóstico y evaluación de la gravedad por medio de pruebas de laboratorio. Boletín Médico del Hospital Infantil de México. 49(3). 165–169.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact